Physician profile
Guy Savir
NPI 1902105372
$3,589.64
in general payments reported to CMS, 2019-2025
44 companies · $712 in 2025
The $712 reported for 2025 was more than what 80% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $237 · 2021: $171 · 2022: $547 · 2023: $641 · 2024: $605 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,958.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $318.45 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $284.16 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $222.37 | 2019-2023 | Imbruvica |
| Daiichi Sankyo INC. | $220.43 | 2019-2025 | Enhertu |
| Incyte Corporation | $210.54 | 2019-2025 | Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $144.28 | 2020-2025 | |
| Astellas Pharma US INC | $142.44 | 2019-2024 | Padcev, Xtandi |
| Astrazeneca Pharmaceuticals LP | $142.24 | 2022-2025 | Imfinzi, Tagrisso, Enhertu |
| Janssen Biotech, INC. | $133.25 | 2020-2025 | Balversa, Akeega, Erleada |
| Eisai INC. | $128.81 | 2019-2023 | |
| Lilly USA, LLC | $127.28 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Regeneron Healthcare Solutions, INC. | $126.14 | 2019-2025 | Libtayo, Lynozyfic |
| Amgen INC. | $118.39 | 2019-2022 | |
| Genzyme Corporation | $108.36 | 2019-2025 | |
| Genentech USA, INC. | $93.39 | 2023-2025 | Polivy, Lunsumio, Venclexta |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Savir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.